Research Analysts Set Expectations for MCRB Q3 Earnings

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Equities research analysts at HC Wainwright cut their Q3 2026 EPS estimates for Seres Therapeutics in a report released on Wednesday, August 5th. HC Wainwright analyst M. Keller now anticipates that the biotechnology company will earn ($1.34) per share for the quarter, down from their prior estimate of ($0.90). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($5.84) per share. HC Wainwright also issued estimates for Seres Therapeutics’ Q4 2026 earnings at ($1.37) EPS, FY2026 earnings at ($4.36) EPS, FY2027 earnings at ($2.06) EPS and FY2028 earnings at ($2.17) EPS.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($2.18) by $2.65. Seres Therapeutics had a negative return on equity of 112.11% and a negative net margin of 1,192.94%.The firm had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.18 million.

Several other equities research analysts have also recently commented on the company. Weiss Ratings cut Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Finally, Zacks Research upgraded Seres Therapeutics to a “hold” rating in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $17.00.

Seres Therapeutics Price Performance

Shares of NASDAQ:MCRB opened at $4.82 on Friday. Seres Therapeutics has a 1 year low of $4.59 and a 1 year high of $29.98. The business’s 50-day moving average is $6.23 and its 200-day moving average is $8.48. The company has a market capitalization of $47.91 million, a price-to-earnings ratio of -1.98 and a beta of 0.20.

Institutional Investors Weigh In On Seres Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its stake in shares of Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 5,157 shares in the last quarter. Barclays PLC lifted its stake in shares of Seres Therapeutics by 427.8% during the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 6,024 shares in the last quarter. ExodusPoint Capital Management LP bought a new position in Seres Therapeutics in the 4th quarter worth approximately $190,000. Goldman Sachs Group Inc. bought a new position in Seres Therapeutics in the 4th quarter worth approximately $213,000. Finally, Invesco Ltd. grew its stake in Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 3,918 shares in the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.